(Q33980062)

30 July 2017

Evaluation of voriconazole pharmacodynamics using time-kill methodology (English)

1 reference

30 July 2017

1 reference

1 reference

5

Pfaller MA

1 reference

30 July 2017

Klepser ME

1

1 reference

30 July 2017

Malone D

series ordinal

2

1 reference

30 July 2017

Lewis RE

series ordinal

3

1 reference

30 July 2017

Ernst EJ

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

Antimicrobial Agents and Chemotherapy

30 July 2017

1 reference

30 July 2017

44

1 reference

30 July 2017

7

1 reference

30 July 2017

1917-1920

1 reference

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Method of reliable determination of minimal lethal antibiotic concentrations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89985

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing

5 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10858354

12 December 2020

inferred from PubMed ID database lookup

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10858354

12 December 2020

inferred from PubMed ID database lookup

In vitro activity of voriconazole against Candida species

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10858354

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1128/AAC.44.7.1917-1920.2000

1 reference

release_5lwrml4xnjbxbgcgi63q4rvs4a

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5lwrml4xnjbxbgcgi63q4rvs4a

24 November 2022

mapped directly with Wikidata item

PMCID

89985

1 reference

30 July 2017

1 reference